FDA warning letters jump 59% as Krieger Scientific flags a compliance gap

The FDA issued 303 drug warning letters in fiscal year 2025, up 59% from the prior year, while early 2026 data shows continued scrutiny. Krieger Scientific says the trend reflects a structural compliance problem in life sciences, not a series of isolated mistakes.

Why it matters: - The warning-letter spike suggests U.S. regulators are tightening pressure on life sciences compliance across validation, calibration and quality systems. - Krieger Scientific argues many companies are still organized around silos that let problems surface only after they become violations. - The FDA’s first warning letter citing inappropriate artificial intelligence use in a Good Manufacturing Practice setting shows oversight is expanding into new operational risks.

What happened: - The FDA issued 303 drug warning letters in fiscal year 2025, up 59% from 190 letters in fiscal year 2024. - Early 2026 data shows no slowdown in enforcement activity. - In April 2026, the FDA issued its first warning letter specifically citing the inappropriate use of artificial intelligence in a Good Manufacturing Practice setting. - Krieger Scientific, a Doylestown, Pennsylvania-based life sciences compliance and technical solutions firm, said the pattern reflects a structural gap in how the industry manages compliance.

The details: - Joseph Morwald, founder and CEO of Krieger Scientific, said the FDA recommended outside compliance expertise in 87% of the warning letters it reviewed last year. - Morwald said validation, calibration and quality functions are often managed in silos by phase, vendor or department, with no single point of accountability. - Morwald said Krieger Scientific was built to cover the full asset lifecycle, rather than only one or two phases. - Krieger Scientific said clients typically bring the firm in wherever support is needed, rather than for an entire program at once. - Morwald said the same team can step into any phase because the full capability already exists behind the service model. - The company said its model is bespoke to each client, but accountability stays consistent across engagements.

Between the lines: - The message is less about one-off compliance misses and more about how life sciences companies are structurally set up to manage regulated work. - Krieger Scientific is positioning itself against the traditional vendor model by selling continuity across the asset lifecycle. - The firm is also linking its growth strategy to the broader compliance burden facing the industry.

What's next: - Krieger Scientific said it recently completed a search for a Head of People and appointed Justin Kane to the role on July 6. - The company said the hire is the first in a series of senior leadership appointments planned in the coming weeks. - Morwald said the company is scaling service capabilities to meet client demand. - Krieger Scientific said it offers Commissioning, Qualification and Validation, Calibration, Owner's Representative, Asset Management, Vendor Managed Services and Project Management services. - The firm said it has national coverage and international partnerships in the United Kingdom, Ireland and Europe. - More information is available at the company's announcement.

The bottom line: - FDA enforcement is rising, and Krieger Scientific says the deeper issue is not more mistakes but a compliance model that leaves no one clearly accountable across the full asset lifecycle.